[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bolt Biotherapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100586934","phase-1-a-first-in-human-study-using-bdc-4182-as-a-single-agent-in-advanced-gastric-and-gastroesophageal-cancer-100586934",false,"NCT06921837","A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer","A Phase 1\u002F2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer","Key Inclusion Criteria:\n\n* Has disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.\n* Subjects must have histologically\u002Fcytologically confirmed gastric or gastroesophageal cancer that is metastatic (Stage 4) or unresectable (Stage 3).\n* Subjects must have received at least 1-2 prior lines of locally available standard therapies or must be intolerant of standard therapies.\n* For subjects in escalation: If prior Claudin 18 IHC expression is known, the subject must have some degree of Claudin 18 expression as defined as Positive or have expression ≥ 1% of tumor cells IHC ≥ 2+. Consult with Medical Monitor as needed.\n* Adequate organ function\n* Agree to have a biopsy prior to enrollment, at acceptable risk in the judgement of the Investigator. If a biopsy is not safely accessible or clinically feasible, an adequate archival tumor sample must be submitted.\n\nKey Exclusion Criteria:\n\n* Known central nervous system (CNS) metastases except for disease that is asymptomatic, clinically stable, and has not required steroids for at least 14 days before starting study treatment.\n* Cardiac disease, pulmonary disease, or hepatic disease\n* Active infection\n* History of inflammatory eye disease\n* Residual toxicity from a previous treatment\n* Any investigational agent or standard anti-cancer therapies within 28 days before starting study treatment or within 5 estimated elimination half-lives, whichever is shorter.","ALL","18 Years",{"count":19,"type":20},122,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers",[27,28],"Gastric Cancer Adenocarcinoma Metastatic","Gastroesophageal Adenocarcinoma",[30,31],"Gastric Cancer","Gastroesophageal Cancer","RECRUITING","2026-01-23",{"date":35,"type":36},"2026-01-27","ACTUAL",{"date":38,"type":36},"2025-05-26",{"date":40,"type":20},"2029-05",{"name":42,"class":43},"Bolt Biotherapeutics, Inc.","INDUSTRY",16,""]